DI
NBIX icon

Disciplined Investments’s Neurocrine Biosciences NBIX Stock Holding History

Disciplined Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4
Closed -$377 – 1032
2023
Q2 		$377 Buy
4
+1
+33% +$98 ﹤0.01% 1333
2023
Q1 		$304 Buy
3
+1
+50% +$104 ﹤0.01% 1388
2022
Q4 		$239 Hold
2
– – ﹤0.01% 1395
2022
Q3 		$0 Buy
+2
New +$203 ﹤0.01% 1471
2022
Q2 		– Sell
-8
Closed -$1K – 1498
2022
Q1 		$1K Buy
+8
New +$678 ﹤0.01% 1088

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Disciplined Investments's NBIX Position: Q3 2023 in Review

Disciplined Investments sold out of Neurocrine Biosciences (NBIX) in Q3 2023, closing a stake of 4 shares — an estimated $377 sold.

Disciplined Investments first reported a position in NBIX in Q1 2022 and held it in 5 quarters. The position peaked at $1K in Q1 2022. 511 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

  • Disciplined Investments reported no remaining Neurocrine Biosciences position as of Q3 2023 after selling out during the quarter.
  • Disciplined Investments sold 4 Neurocrine Biosciences shares in Q3 2023, an estimated $377.
  • Disciplined Investments first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 5 quarters.
  • Disciplined Investments's Neurocrine Biosciences position peaked at $1K in Q1 2022.
  • 511 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.